암 면역요법 시장 : 치료법별, 작용기전별, 치료 단계별, 투여 경로별, 적응증별, 최종 사용자별 예측(2026-2032년)

The Cancer Immunotherapy Market is projected to grow by USD 244.72 billion at a CAGR of 7.52% by 2032.

Cancer Immunotherapy Executive Summary

Cancer immunotherapy has moved from a specialized oncology approach to a core pillar of cancer treatment, reshaping standards of care across hematologic malignancies and solid tumors. Immune checkpoint inhibitors, CAR-T cell therapies, bispecific antibodies, antibody-drug conjugate combinations, therapeutic cancer vaccines, oncolytic viruses, cytokine-based therapies, and tumor-infiltrating lymphocyte therapies are now central to clinical and commercial strategies.

The growth imperative is supported by verified epidemiology. The International Agency for Research on Cancer reported approximately 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022 and projects more than 35 million new cancer cases by 2050. This rising burden is accelerating demand for durable, biomarker-guided, and combination-based immuno-oncology treatments that can improve survival while supporting precision medicine adoption.

Transformative Shifts in the Immunotherapy Landscape

The cancer immunotherapy landscape is being transformed by a shift from single-agent therapies toward rational combinations, earlier-line treatment, and biomarker-selected patient populations. PD-1, PD-L1, and CTLA-4 inhibitors established immuno-oncology as a mainstream treatment category, while next-generation modalities are addressing resistance, relapse, and tumor microenvironment suppression.

Manufacturing and delivery models are also changing. Autologous cell therapy capacity, allogeneic platforms, decentralized manufacturing, vein-to-vein logistics, and real-world evidence programs are becoming competitive differentiators. At the same time, payers and health technology assessment agencies are applying stricter scrutiny to durability, quality-adjusted survival, safety management, and total cost of care.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across cancer immunotherapy discovery, development, and commercialization. AI-enabled target discovery, antigen prediction, neoantigen prioritization, spatial biology analysis, digital pathology, and multimodal biomarker modeling are helping researchers identify patients most likely to respond and design more precise treatment strategies.

In clinical operations, AI supports trial matching, eligibility screening, site selection, adverse event signal detection, and real-world evidence generation. The most immediate value is not replacing clinical judgment but improving decision speed, reducing failed enrollment, and strengthening companion diagnostic strategies. Leaders that combine AI governance, high-quality datasets, and regulatory-grade validation are positioned to accelerate immuno-oncology innovation responsibly.

Key Regional Insights

North America remains a global center for cancer immunotherapy innovation due to dense clinical trial networks, advanced academic cancer centers, FDA regulatory pathways, and strong biopharma financing. The United States anchors early adoption of checkpoint inhibitors, cell therapies, bispecific antibodies, and biomarker testing, while Canada contributes through public health systems, oncology research networks, and precision medicine initiatives supported by evidence-based reimbursement review.

Europe is shaped by EMA oversight, national reimbursement systems, and health technology assessment requirements that prioritize evidence quality, cost-effectiveness, and real-world outcomes. Asia-Pacific is expanding as China, Japan, South Korea, India, and Australia increase clinical research output, biologics manufacturing, regulatory modernization, and oncology infrastructure. Latin America, led by Brazil and Mexico, is improving specialty access and clinical trial participation but continues to face affordability, pathology, and molecular diagnostic capacity constraints. The Middle East, particularly GCC markets, is investing in tertiary cancer centers, genomic medicine, and specialty procurement, while Africa's opportunity depends on strengthening pathology, cold-chain logistics, oncology workforce capacity, pharmacovigilance, and equitable access programs.

Key Group Insights

The G7 continues to drive premium immuno-oncology innovation through mature regulatory systems, high clinical trial density, specialized cancer centers, and established reimbursement pathways, making it a critical launch environment for checkpoint inhibitors, cell therapies, bispecific antibodies, and companion diagnostics. NATO markets overlap with many advanced oncology systems and also highlight the importance of secure pharmaceutical supply chains, data protection, cyber-resilient clinical infrastructure, and resilient biologics manufacturing.

The European Union benefits from centralized EMA authorization and a growing emphasis on joint health technology assessment, which can improve market consistency while maintaining pressure on comparative effectiveness and value demonstration. BRICS countries offer population scale, expanding clinical research participation, increasing domestic biologics capacity, and rising demand for oncology access, though availability varies significantly by reimbursement, diagnostics, and infrastructure. ASEAN markets are advancing unevenly, with Singapore, Thailand, and Malaysia showing stronger specialty oncology capabilities, while broader regional adoption depends on workforce development, pathology access, and affordability. GCC countries are using national transformation agendas to expand precision oncology, specialty procurement, genomic medicine, and regional cancer care hubs.

Key Country Insights

The United States leads cancer immunotherapy commercialization through FDA approvals, advanced biomarker testing, broad clinical trial access, academic cancer networks, and strong life sciences financing. Canada emphasizes evidence-based adoption through provincial reimbursement systems and pan-Canadian oncology assessment processes. Mexico and Brazil represent important Latin American access markets, with progress tied to public-private oncology capacity, specialty distribution, clinical research participation, and diagnostic expansion.

In Europe, the United Kingdom combines NHS real-world evidence capabilities with strong oncology research, while Germany and France are central to reimbursement evaluation, clinical adoption, and biomarker testing infrastructure. Italy and Spain contribute robust oncology networks and expanding access to precision medicine, while Russia maintains domestic oncology demand despite geopolitical, regulatory, and supply access complexity. In Asia-Pacific, China has become a major immuno-oncology development engine supported by large clinical trial activity and domestic biologics capacity; India offers large patient populations, expanding biosimilar capabilities, and rising oncology infrastructure; Japan supports high-quality regulatory and clinical infrastructure with strong adoption of innovative oncology therapies; South Korea is strong in biologics, digital health, and cell therapy innovation; and Australia remains a preferred clinical trial destination with globally respected cancer centers and strong translational research capabilities.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker-led development, combination strategies with clear mechanistic rationale, and trial designs that demonstrate durable benefit in defined patient segments. Strong companion diagnostic planning, inclusive enrollment, decentralized trial capabilities, and real-world evidence generation are essential to improve clinical utility, regulatory confidence, and payer acceptance.

Manufacturers should strengthen cell and gene therapy supply chains, invest in scalable manufacturing, and build capabilities for adverse event management, including cytokine release syndrome and immune-related toxicities. Commercial teams should prepare access dossiers that address survival, quality of life, durability, site-of-care economics, and long-term value. Partnerships with academic centers, diagnostic developers, AI platforms, contract manufacturers, and regional health systems can accelerate access, operational resilience, and differentiation.

Research Methodology

The executive summary is developed using a secondary research approach grounded in publicly available and authoritative sources, including cancer epidemiology from international health agencies, regulatory information from major agencies, clinical trial registries, peer-reviewed oncology literature, health technology assessment practices, oncology guideline updates, and immuno-oncology development activity.

The methodology emphasizes triangulation across epidemiological data, therapeutic approvals, clinical development patterns, regional healthcare infrastructure, reimbursement dynamics, manufacturing considerations, diagnostics adoption, and technology signals. Insights are synthesized to support strategic decision-making for executives, investors, manufacturers, diagnostics developers, healthcare providers, and policy stakeholders operating across the cancer immunotherapy value chain.

Conclusion

Cancer immunotherapy is entering a more complex and value-driven phase defined by precision biomarkers, advanced biologics, engineered cell therapies, AI-enabled discovery, and regional access differentiation. The sector's long-term opportunity is supported by rising global cancer incidence and continued clinical progress across both hematologic malignancies and solid tumors.

Sustainable leadership will depend on evidence generation, scalable manufacturing, equitable access, diagnostic readiness, and disciplined access strategies. Organizations that align innovation with measurable patient outcomes, safety management, real-world value, and payer expectations will be best positioned to compete in the evolving global cancer immunotherapy landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cancer Immunotherapy Market, by Therapy Type

• 7.1. Cancer Vaccines
• 7.2. CAR-T Therapy
• 7.3. CTLA-4 Inhibitors
• 7.4. Oncolytic Virus Therapy
• 7.5. PD-1 Inhibitors
• 7.6. PD-L1 Inhibitors

8. Cancer Immunotherapy Market, by Mechanism Of Action

• 8.1. Adoptive Cell Transfer
• 8.2. Checkpoint Inhibitors
• 8.3. Cytokine Therapy
• 8.4. Oncolytic Virus Therapy
• 8.5. Vaccine Therapy

9. Cancer Immunotherapy Market, by Line Of Therapy

• 9.1. First Line
• 9.2. Fourth Line And Beyond
• 9.3. Second Line
• 9.4. Third Line

10. Cancer Immunotherapy Market, by Route Of Administration

• 10.1. Intratumoral
• 10.2. Intravenous
• 10.3. Subcutaneous

11. Cancer Immunotherapy Market, by Indication

• 11.1. Hematologic Malignancies
  • 11.1.1. Leukemia
  • 11.1.2. Lymphoma
  • 11.1.3. Multiple Myeloma
• 11.2. Solid Tumors
  • 11.2.1. Breast Cancer
  • 11.2.2. Colorectal Cancer
  • 11.2.3. Lung Cancer
  • 11.2.4. Melanoma

12. Cancer Immunotherapy Market, by End User

• 12.1. Hospitals
• 12.2. Research Institutes
• 12.3. Specialty Clinics

13. Cancer Immunotherapy Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Cancer Immunotherapy Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Cancer Immunotherapy Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Adaptimmune Therapeutics
• 17.2. Amgen Inc.
• 17.3. Astellas Pharma Inc.
• 17.4. AstraZeneca PLC
• 17.5. Bayer AG
• 17.6. BeiGene, Ltd.
• 17.7. BioNTech SE
• 17.8. Boehringer Ingelheim
• 17.9. Bristol-Myers Squibb Company
• 17.10. Cellectis S.A.
• 17.11. Daiichi Sankyo Company, Limited
• 17.12. Eli Lilly and Company
• 17.13. Fate Therapeutics, Inc.
• 17.14. Gilead Sciences, Inc.
• 17.15. GlaxoSmithKline plc
• 17.16. Immunocore Holdings PLC
• 17.17. Iovance Biotherapeutics, Inc.
• 17.18. Johnson & Johnson
• 17.19. Merck & Co.
• 17.20. Moderna, Inc.
• 17.21. Novartis AG
• 17.22. Pfizer Inc.
• 17.23. Regeneron Pharmaceuticals, Inc.
• 17.24. Roche Holding AG
• 17.25. Sanofi
• 17.26. Takeda Pharmaceutical Company